Kratom (Mitragyna speciosa) contains alkaloids that interact with several receptor systems in the human body. The most studied interactions involve opioid receptors, especially the mu-opioid receptor. However, kratom alkaloids also show activity at adrenergic and serotonin receptors in laboratory research. These receptor interactions help explain why kratom’s effects are complex and dose-dependent. WHO
Mitragynine and 7-hydroxymitragynine are considered partial agonists at the mu-opioid receptor. A partial agonist activates a receptor, but not to the same level as a full agonist like morphine. Laboratory studies show that 7-hydroxymitragynine has stronger binding affinity at the mu-opioid receptor compared to mitragynine, even though it is naturally present in much lower amounts in raw leaf. NIH/PMC
Research also suggests that kratom alkaloids may signal through G-protein pathways with less recruitment of beta-arrestin compared to some traditional opioids in experimental models. This concept is sometimes described as “biased agonism” or “functional selectivity.” Scientists continue studying whether this signaling difference meaningfully changes risk profiles in real-world use. Nature Scientific Reports
In addition to opioid receptors, mitragynine has demonstrated activity at adrenergic receptors in laboratory settings. Adrenergic receptors are involved in alertness, blood pressure regulation, and the stress response. This receptor interaction may help explain why lower amounts of kratom are sometimes reported as stimulating rather than sedating. NIH/PMC
Metabolism is another major factor in receptor interaction. After ingestion, mitragynine is processed in the liver by enzymes such as CYP3A4. Some evidence shows that mitragynine can be converted into 7-hydroxymitragynine in human liver systems. Because 7-OH has stronger mu-opioid receptor activity, this metabolic step may influence intensity and duration of effects. NIH/PMC
Drug interactions are an important safety concern. In vitro research indicates that mitragynine can inhibit certain CYP enzymes, including CYP2D6 and CYP3A4. These enzymes metabolize many prescription medications. If enzyme activity is altered, blood levels of other drugs could potentially increase or decrease, depending on the combination. NIH/PMC
Overall, kratom’s receptor activity is not limited to one pathway. It involves partial activation of opioid receptors, possible signaling bias, adrenergic interactions, and liver metabolism that changes chemical structure inside the body. From a plant science perspective, this multi-pathway interaction is why kratom is considered pharmacologically complex and continues to be studied in regulatory and research settings. WHO
All information presented is for educational purposes only and focuses on plant science research and emerging studies. This content does not replace professional medical advice. Always consult licensed healthcare providers or trained professionals in plant-based science and natural health disciplines. All information provided is thought to be put to date with modern research and you should still do your own research and consult with professionals.
